Phaseline

Targets › HGF

HGF (Hepatocyte growth factor): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 2 Phase 1, 2 Phase 3; Ophthalmology, Oncology, Respiratory; next expected readout Feb 2027.

Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. (UniProt, P14210)

Open in Phaseline: the race on HGF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kringle PharmaKP-100LI
Recombinant human hepatocyte growth factor (HGF)
HGFPhase 3Vocal Fold ScarFeb 2027
AVEO PharmaceuticalsFiclatuzumab (AV-299)
Hepatocyte growth factor inhibitor
HGFPhase 3Metastatic Head-and-neck Squamous-cell CarcinomaAug 2027
Claris BiotherapeuticsCSB-001 Ophthalmic Solution 0.1%
Human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
HGFPhase 1Corneal Scar; Limbal Stem Cell DeficiencyJun 2027

Conditions

Corneal Scar (1) Limbal Stem Cell Deficiency (1) Metastatic Head-and-neck Squamous-cell Carcinoma (1) Vocal Fold Scar (1)

Modalities

protein or peptide (1), antibody (1), small molecule (1)

Companies

Claris Biotherapeutics (1) AVEO Pharmaceuticals (1) Kringle Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.